Trial Profile
A phase II, multicentre study to evaluate the long-term safety and efficacy of MT-1303 in subjects with relapsing-remitting multiple sclerosis who have completed the MT-1303-E04 study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Amiselimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms Momentum
- Sponsors Mitsubishi Tanabe Pharma America; Mitsubishi Tanabe Pharma Corporation
- 08 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 01 Jul 2013 Planned end date changed from 10 Jan 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.